<DOC>
	<DOCNO>NCT00121966</DOCNO>
	<brief_summary>The primary objective study : - To investigate whether insulin aspart meal well standard treatment insulin NPH bedtime , evaluate HbA1c . The secondary objective study : - To study combination treatment metformin and/or rosiglitazone insulin aspart meal well standard treatment insulin NPH combine one oral antidiabetic drug . According hypothesis , special focus give treatment group insulin aspart combine metformin rosiglitazone . The treatment effect evaluate HbA1c . - To examine effect treatment glucose metabolism beta cell function , evaluate diurnal blood glucose , fast plasma glucose , insulin , C-peptide , lactate . - To examine effect treatment cardiovascular risk factor evaluate serum lipid profile , serum free fatty acid , urine albumin/creatinine ratio , electrocardiogram ( ECG ) . - To quantify describe patient ' subjective experience two different insulin treatment ( quality life assessment ) - To examine patient type 2 diabetes presence variability series gene , know assume : - affect long term outcome ; - determine responsiveness treatment diet , exercise drug target know risk marker late diabetic complication ; - intervention , analyse complex interrelationship genotype clinical endpoint responsiveness actual treatment modality .</brief_summary>
	<brief_title>South Danish Diabetes Study : Evaluation Antidiabetic Treatment Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Ages 30 70 year Fasting Cpeptide &gt; 300 pmol/l Body mass index ( BMI ) &gt; 25 kg/m2 Diabetes 2 year Pharmacological antidiabetic treatment 3 month 7.0 % &lt; HbA1c &lt; 12.0 % randomisation Patient willing sign inform consent Fertile woman : negative pregnancy test use oral intrauterine contraception depot gestagen . Screatinine &gt; 120 Î¼mol/l History intolerance metformin glitazones SALAT/SASAT &gt; 2.5 x upper normal limit Total cholesterol &gt; 10 mmol/l Total triglyceride &gt; 8 mmol/l Hemoglobin ( Hb ) &lt; normal range Treatment glitazone precede 30 day New York Heart Association ( NYHA ) functional class III IV Night work Present plan pregnancy Poor vision impede insulin administration Unawareness hypoglycaemia ( complete partly ) Mental illness alcohol abuse Clinically relevant major organ systemic illness Uncontrolled hypertension &gt; 180/110 mmHg , systolic diastolic Steroid treatment Severe lung disease A history malign disease An expectation patient collaborative able understand character trial</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Insulin Aspart</keyword>
	<keyword>Insulin NPH</keyword>
	<keyword>Metformin</keyword>
	<keyword>Rosiglitazone</keyword>
</DOC>